GlobalData has estimated that the global Crohn’s Disease therapeutics market was worth $4.4 billion in 2012
GlobalData estimates that the global GVHD therapeutics market was worth $261.6m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach $615.1m by 2018.
Bell Potter has previously noted (Feb 2014) in one of their research reports that GVHD could be a US$300 - $600m and Crohns Disease a US$2.4bn market. In Bell Potters 12 month price target (approx. $9 +), Prochymal has not been factored into their valuation and noted as such -
Based on recent 29/4/14 ASX release ..and CNBC interviews (all posted before) SI quite excited by the potential of Prochymal...in fact MSB's evaluation of the Osiris data at the time , was a major reason why they outlaid $50M + in acquiring their MSC technology.
On 28/5/2014 ASX release about MSB also accelerating there manufacturing plans in Singapore also made reference to Prochymal.
Please DYOR and GLTAH.
- Forums
- ASX - By Stock
- Prochymal
GlobalData has estimated that the global Crohn’s Disease...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.47 |
Change
-0.038(2.48%) |
Mkt cap ! $1.681B |
Open | High | Low | Value | Volume |
$1.45 | $1.50 | $1.45 | $6.152M | 4.195M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 17585 | $1.47 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.48 | 8394 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 21885 | 1.470 |
11 | 56888 | 1.465 |
6 | 25050 | 1.460 |
6 | 60223 | 1.455 |
22 | 185204 | 1.450 |
Price($) | Vol. | No. |
---|---|---|
1.475 | 3659 | 8 |
1.480 | 48142 | 9 |
1.485 | 79752 | 7 |
1.490 | 112305 | 9 |
1.495 | 29411 | 5 |
Last trade - 14.08pm 08/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |